Ondansetrom Aurovitas (Ondansetron)

Ondansetron, the active ingredient in Ondansetrom Aurovitas, is a serotonin 5‑HT3 receptor antagonist presented as a tablet for oral use. It is used to prevent nausea and vomiting caused by chemotherapy, radiotherapy and surgery in adult and paediatric patients.

GNH USA supplies Ondansetrom Aurovitas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Ondansetron acts on the serotonergic pathway to control nausea and vomiting in several clinical settings. - Chemotherapy‑induced nausea and vomiting (CINV): helps prevent and treat acute and delayed episodes. - Radiotherapy‑induced nausea and vomiting (RINV): reduces the frequency and severity of symptoms. - Post‑operative nausea and vomiting (PONV): decreases incidence after general anaesthesia. - Pregnancy‑associated nausea (hyperemesis gravidarum): used when benefits outweigh risks, under specialist supervision.

Side‑effect profiles reflect the drug’s pharmacology and are generally mild to moderate.

Common Side Effects: - Headache: mild to moderate intensity. - Constipation: reduced bowel motility. - Diarrhoea: occasional loose stools. - Fatigue: feeling of tiredness. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - QT‑interval prolongation: may predispose to cardiac arrhythmias. - Severe hypersensitivity: rash, angio‑edema or anaphylaxis. - Serotonin syndrome: rare when combined with other serotonergic agents. - Hepatic dysfunction: elevated liver enzymes in susceptible individuals.

When prescribing ondansetron, clinicians should consider patient‑specific factors and monitor for adverse reactions. - Cardiac risk assessment: evaluate baseline ECG in patients with known QT prolongation. - Electrolyte balance: correct hypokalaemia or hypomagnesaemia before use. - Drug‑interaction review: avoid concurrent use with other QT‑prolonging agents. - Pregnancy and lactation: use only if clearly needed, after risk‑benefit analysis. - Renal/hepatic impairment: dose adjustment may be required in severe dysfunction. - Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture.

Ondansetron may interact with several drug classes, altering cardiac rhythm or serotonergic activity.

Major Interactions (Avoid): - Other QT‑prolonging drugs (e.g., quinidine, haloperidol): increased risk of torsades de pointes. - Apomorphine: can cause profound hypotension and loss of consciousness.

Moderate Interactions (Monitor Closely): - Antidepressants (SSRIs, SNRIs, MAOIs): potential for serotonin syndrome. - Antifungal azoles (ketoconazole, fluconazole): may raise ondansetron plasma levels. - Macrolide antibiotics (erythromycin, clarithromycin): modest increase in QT interval. - Calcium channel blockers (diltiazem, verapamil): may enhance QT prolongation. - Digoxin: slight increase in serum concentration.